Active Biotech AB Interim report January - March 2015


LUND, Sweden, April 23, 2015 (GLOBE NEWSWIRE) -- Laquinimod

  • The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016
  • Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25 

Tasquinimod     

  • Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
  • Further development of tasquinimod for the treatment of prostate cancer has been discontinued. The collaboration agreement with Ipsen will accordingly cease.

ISI          

  • The project is currently focusing on building up a patent portfolio

Financial summary

MSEK  Jan. - Mar. Jan. - Dec.
 20152014 2014 
Net sales2.92.1 10.4 
      
Operating loss-57.4-59.2 -228.5 
Loss for the period-58.0-60.2 -231.5 
Loss per share (SEK)-0.64-0.80 -3.02 
Cash and cash equivalents 270.5298.5 328.5 

 For further information, please contact:                    

  Tomas Leanderson, President and CEO
  Tel: +46 (0)46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44
  The report is also available at www.activebiotech.com
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
   

Active Biotech AB Interim report January - March 2015 http://hugin.info/1002/R/1913651/683571.pdf

HUG#1913651